Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsKey papers
ScholarIQanswers from OpenAlex & ORCID

Martha Mayo

ResearcherPublications, citations & collaboration network

Martha Mayo is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 67 works, 4,076 citations, an h-index of 22 and an i10-index of 29.

67
Works
4,076
Citations
22
h-index
29
i10-index

How has Martha Mayo's publication output changed over time?

ScholarIQpublication output · 2002–2020

Output grew0% over the shown period — from 1 works in 2002 to 1 in 2020.

1
1
1
1
2
1
2
1
1
1
2002200320042006201320142015201720192020

What are the most-cited papers on Martha Mayo?

ScholarIQmost cited works
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Matthew R. Weir, George L. Bakris, David A. Bushinsky, Martha Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ‐Schmidt, Lance Berman, Bertram Pitt
New England Journal of Medicine. 2014668 CitationsOPEN ACCESS
Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS
Peter S. Staats, Thomas Yearwood, Steven G. Charapata, R. Presley, Mark S. Wallace, Michael G. Byas‐Smith, Robert B. Fisher, David A. Bryce, Eugene A. Mangieri, Robert R. Luther, Martha Mayo, Dawn McGuire, David Ellis
JAMA. 2004646 Citations
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
George L. Bakris, Bertram Pitt, Matthew R. Weir, Mason W. Freeman, Martha Mayo, Dahlia Garza, Yuri Stasiv, Rezi Zawadzki, Lance Berman, David A. Bushinsky
JAMA. 2015440 Citations
Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis
Gerald D. Silverberg, Martha Mayo, Thomas Saul, Edward Rubenstein, Dawn McGuire
S70053155. 2003433 Citations
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Rajiv Agarwal, Patrick Rossignol, Alain Romero, Dahlia Garza, Martha Mayo, Suzette Warren, Jia Ma, William B. White, Bryan Williams
The Lancet. 2019371 CitationsOPEN ACCESS

Related on ScholarIQ

University of Connecticut
Institution
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Paper
Intrathecal Ziconotide in the Treatment of Refractory Pain in Patients With Cancer or AIDS
Paper
Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease
Paper
Alzheimer's disease, normal‐pressure hydrocephalus, and senescent changes in CSF circulatory physiology: a hypothesis
Paper
Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial
Paper
470M+ articles · free account